文献速递临床试验与 GCP流行病学与生物统计

多组分行为干预促进饮水预防尿路结石的随机临床试验

Prevention of urinary stones with hydration: a randomised clinical trial of an adherence intervention.
PubMed 文献 · Lancet · 2026-01-01

本研究在美国6个学术医学中心纳入1658例有尿路结石病史且24小时尿量偏低的≥12岁患者,随机分为多组分行为干预组与指南一致性照护对照组。

要点

  • 干预组24小时尿量在第6、12、18、24个月均高于对照组。
  • 干预组第6、12个月尿频、尿急、夜尿症状多于对照组。

核心结论

  • 促进饮水的多组分行为干预未减少症状性结石复发,但较指南照护适度增加尿量。

研究设计与样本

  • 随机临床试验,在美国6个学术医学中心纳入1658例≥12岁有尿路结石病史且24小时尿量偏低患者,1:1随机分干预组(n=826)与对照组(n=832)。

主要发现

  • 干预组24小时尿量在第6、12、18、24个月均高于对照组。
  • 干预组第6、12个月尿频、尿急、夜尿症状多于对照组,其他时间点无差异。
  • 两组结石增长≥2 mm或新发结石无差异,复合结局亦无统计学差异。
  • 无因低钠血症住院事件;干预组12例(1%)无症状性低钠血症,对照组2例(<1%)。

临床怎么用

  • 行为干预可适度增加尿量,但未证明能降低结石复发,需权衡泌尿症状负担。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Increased fluid intake is universally recommended to decrease the risk of recurrent urinary stones; however, adherence is challenging. The effectiveness of interventions to maintain high fluid intake has not been well studied. We sought to determine whether a multicomponent behavioural intervention programme to promote high fluid intake reduces symptomatic stone recurrence, compared with a control. METHODS: In this randomised clinical trial, participants aged 12 years and older with a history of urinary stone disease and low 24 h urine volumes based on current guidelines were enrolled at six academic medical centres in the USA. Participants were randomly assigned in a 1:1 ratio to a multicomponent behavioural intervention designed to promote increased fluid intake or to the control group receiving guideline-concordant care. The intervention consisted of a fluid prescription, financial incentives to adhere to fluid prescription, health coaching to overcome barriers to consuming more fluids, and patient-selected approaches such as text messaging to maintain increased fluid intake. Randomisation assignment was computer-generated remotely, and investigators, treating physicians, outcome assessors, and adjudicators were masked to group assignment. The primary outcome was symptomatic stone recurrence defined as stone passage or procedural intervention for stone(s) during a 2-year follow-up period, analysed in the intention-to-treat population. Secondary outcomes included change in 24 h urine volume, urinary symptoms, radiographic stone recurrence or growth, and a composite outcome of symptomatic stone recurrence, new stone formation, and growth of existing stone(s); hyponatremia requiring hospitalisation was the safety endpoint. This trial is registered with ClinicalTrials.gov, NCT03244189. FINDINGS: Between Oct 26, 2017, and Feb 18, 2022, 1658 participants were randomly assigned to intervention (n=826) and control (n=832) groups (median age 44 years [IQR 29-59]; 946 [57%] female). At a median follow-up of 738 days (IQR 711-778), symptomatic stone events occurred in 154 (19%) participants in the intervention group and 165 (20%) in the control group (hazard ratio 0·96, 95% CI 0·77-1·20). Among these 1658 participants, 1104 (66·6%) were recurrent stone formers. 24 h urine volume increased from baseline in both groups and was higher in the intervention group at months 6, 12, 18, and 24 compared with the control group. Urinary storage symptoms of frequency, urgency, and nocturia were greater in the intervention group versus control at months 6 and 12 but not at other timepoints. There was no difference in stone growth of at least 2 mm or new stones between groups from baseline to end-of-study imaging, and the composite outcome of symptomatic stone recurrence, new stone formation, or stone growth of at least 2 mm was also not statistically different between groups. No episodes of hyponatremia requiring hospitalisation (safety endpoint) were reported; 12 (1%) participants in the intervention group had asymptomatic hyponatraemia versus two (<1%) participants in the control group. INTERPRETATION: A behavioural intervention programme to promote fluid intake for secondary stone prevention did not reduce recurrent stone events but modestly increased urine volume compared with guideline-based care during a 2-year follow-up period. FUNDING: National Institute of Diabetes and Digestive and Kidney Diseases.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Desai AC, Maalouf NM, Harper JD, et al. Prevention of urinary stones with hydration: a randomised clinical trial of an adherence intervention. Lancet. 2026. PMID: 41864748. doi:10.1016/S0140-6736(25)02637-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。